Help Your Patients Access Biologic Treatments
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=42%2C0%2C693%2C447&w=310&h=200)
27% of biologic users with commercial insurance reported cost of treatment was a barrier to treating the psoriatic disease.
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=42%2C0%2C693%2C447&w=310&h=200)
On average, biologic users reported that help navigating health insurance was of greater importance to them than non-biologic users (p=.001).
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=42%2C0%2C693%2C447&w=310&h=200)
On average, biologic users (3.86) reported that help finding resources to lower cost or access to treatments was of greater importance to them than non-biologic users (3.57) (p<.001).
Understanding resources to access treatment is key
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=42%2C0%2C693%2C447&w=310&h=200)
Approximately 80% of biologic users with private, commercial insurance use a manufacturer copay card to help pay for their medication.
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=42%2C0%2C693%2C447&w=310&h=200)
Approximately 67% of biologic users with commercial insurance who use a co-pay assistance program would not be able to afford their treatment without this assistance.
Medical professionals who help patients access and fulfill their biologic prescriptions are critical. They work collaboratively with patients to:
Communicate effectively
Through proactive education and information at the time of prescription, patients’ expectations can be managed.
Obtain up-to-date information
There is critical information required by payers and specialty pharmacies.
Fight denials
Challenging coverage denials can be part of the biologic fulfilment process.
View more resources
National Psoriasis Foundation. 2020. Annual Survey of Individuals with Psoriasis in the United States. Unpublished raw data.